Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Baxter
Harvard Business School
Colorcon
Boehringer Ingelheim

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Ortho Mcneil Janssen Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for ORTHO MCNEIL JANSSEN, and what generic and branded alternatives to ORTHO MCNEIL JANSSEN drugs are available?

ORTHO MCNEIL JANSSEN has seven approved drugs.



Summary for Ortho Mcneil Janssen
US Patents:0
Tradenames:9
Ingredients:6
NDAs:7

Drugs and US Patents for Ortho Mcneil Janssen

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ortho Mcneil Janssen ORTHO-NOVUM 1/50 28 mestranol; norethindrone TABLET;ORAL-28 016709-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ortho Mcneil Janssen TOLECTIN DS tolmetin sodium CAPSULE;ORAL 018084-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Ortho Mcneil Janssen ORTHO-NOVUM 10/11-21 ethinyl estradiol; norethindrone TABLET;ORAL-21 018354-001 Jan 11, 1982 DISCN Yes No   Start Trial   Start Trial
Ortho Mcneil Janssen DITROPAN oxybutynin chloride SYRUP;ORAL 018211-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial
Ortho Mcneil Janssen TOLECTIN 600 tolmetin sodium TABLET;ORAL 017628-002 Mar 8, 1989 DISCN No No   Start Trial   Start Trial
Ortho Mcneil Janssen URISPAS flavoxate hydrochloride TABLET;ORAL 016769-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ortho Mcneil Janssen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ortho Mcneil Janssen VIADUR leuprolide acetate IMPLANT;IMPLANTATION 021088-001 Mar 3, 2000 6,132,420   Start Trial
Ortho Mcneil Janssen TOLECTIN tolmetin sodium TABLET;ORAL 017628-001 Approved Prior to Jan 1, 1982 3,752,826   Start Trial
Ortho Mcneil Janssen TOLECTIN DS tolmetin sodium CAPSULE;ORAL 018084-001 Approved Prior to Jan 1, 1982 3,752,826   Start Trial
Ortho Mcneil Janssen VIADUR leuprolide acetate IMPLANT;IMPLANTATION 021088-001 Mar 3, 2000 6,156,331   Start Trial
Ortho Mcneil Janssen VIADUR leuprolide acetate IMPLANT;IMPLANTATION 021088-001 Mar 3, 2000 6,235,712   Start Trial
Ortho Mcneil Janssen VIADUR leuprolide acetate IMPLANT;IMPLANTATION 021088-001 Mar 3, 2000 6,124,261   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
McKinsey
Medtronic
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.